PharmAust (ASX: PAA) progresses flagship Monepantel drug in treating canine lymphoma and COVID-19 (w/ Roger Aston)

PharmAust (ASX: PAA) executive chairman and CEO Dr Roger Aston joins Small Caps to discuss the company’s Monepantel drug and its antiviral potential after laboratory results have consistently shown it can interfere with the proliferation of SARS-CoV2, the virus causing COVID-19. More advanced trials for Monepantel are also underway, where it is being used to treat canine lymphoma. This phase IIb trial is evaluating Monepantel in treatment-naïve B cell lymphoma, with this study still recruiting and progressing.See omnystudio.com/listener for privacy information.